Older Americans Quit Weight-Loss Drugs in Droves
nytimes.com
Saved by David Mandel
Older Americans Quit Weight-Loss Drugs in Droves
et’s be clear: For those who need them — medically rather than cosmetically — the drugs are a godsend. The primary indication for Ozempic and Mounjaro — and the only condition they are currently FDA-approved for — is the treatment of type-2 diabetes (the lifestyle-contingent, typically adult-onset diabetes, as opposed to the rarer type-1 diabetes,... See more
Article
A majority of people prescribed GLP-1 drugs stop using it within the first year. Maybe it’s the side effects. Maybe they miss drinking and don’t appreciate the nausea. Maybe they can’t afford the drugs. Maybe they stop after they hit their target weight. Maybe people just don’t like injectables.
If GLP-1 Drugs Are Good For Everything, Should We All Be on Them?
The appetite for weight-loss drugs, known as glp-1 agonists, has been insatiable since they hit the market a decade ago. In 2024 global spending on them reached $54bn, a figure that is sure to rise in the coming years. These drugs, better known under their brand names of Wegovy, Ozempic, Mounjaro and Zepbound, do not merely promise trimmer
... See moreWeight loss and disordered eating communities have long had a presence on social media platforms like X (formerly Twitter), Tumblr, YouTube, WeHeartIt, and Instagram. But in the past few years, weight loss content on TikTok was intensified by the development and popularity of GLP-1 medications like Ozempic, Mounjaro, and Wegovy. Many experts and... See more